TAGRISSO (osimertinib)

TAGRISSO (osimertinib) is an EGFR TKI indicated for adult patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).1

Prescribing information

Tolerability

Most adverse events with TAGRISSO in the AURA3 clinical trial were mild to moderate (see study details below).2

AEs at a maximum grade of 1 were reported in 33% of the TAGRISSO group and in 11% of the platinum–pemetrexed group. AEs seen with platinum-pemetrexed tended to be more severe, despite the longer treatment duration with TAGRISSO.2
Any grade
Any grade
Grade 3
Grade 3